Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 9:4:299-305.
doi: 10.1016/j.bbrep.2015.10.003. eCollection 2015 Dec.

Production, in Pichia pastoris, of a recombinant monomeric mapacalcine, a protein with anti-ischemic properties

Affiliations

Production, in Pichia pastoris, of a recombinant monomeric mapacalcine, a protein with anti-ischemic properties

A Noubhani et al. Biochem Biophys Rep. .

Abstract

Mapacalcine is a small homodimeric protein of 19 kDa with 9 disulfide bridges extracted from the Cliona vastifica sponge (Red Sea). It selectively blocks a calcium current insensitive to most calcium blockers. Specific receptors for mapacalcine have been described in a variety of tissues such as brain, smooth muscle, liver, and kidney. Previous works achieved on hepatocytes and nervous cells demonstrated that this protein selectively blocks a calcium influx triggered by an ischemia/reperfusion (I/R) shock and efficiently protects cells from death after I/R. The aim of this work was to produce the recombinant mapacalcine in the yeast Pichia pastoris. Mass spectrometry, light scattering analysis and biological characterization demonstrated that the recombinant mapacalcine obtained was a monomeric form with 4 disulfide bridges which retains the biological activity of the natural protein.

Keywords: Calcium; Ischemia/reperfusion; Mapacalcine; Pichia pastoris; Protein production.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Synthetic gene construction of mapacalcine from its aminoacid sequence. A: Mapacalcine monomer (89 aminoacids) and its deduced synthetic gene sequence (270 nucleotides). B: Map of the expressed 9HIS-mapacalcine cassette inserted in Pichia pastoris genome.
Fig. 2
Fig. 2
Purification steps of 9HIS-mapacalcine. A: Elution profile (280 nm) obtained during the size exclusion chromatography step. Vertical lines delimitate the different pools. B: SDS PAGE (Coomassie staining) and WB analyses of pools P1–P4. C: Chromatogram (280 nm) obtained after injection of pool P1 on the C8 reverse phase column. Vertical lines indicate the recombinant mapacalcine.
Fig. 3
Fig. 3
ESI-MS analysis of 9HIS-mapacalcine. Deconvoluted spectra and zooms on regions of interest. 9HIS-mapacalcine was analyzed after different treatments: A: Untreated. B: treated with DTT. C: treated with iodoacetamide.
Fig. 4
Fig. 4
Effects of 9HIS-mapacalcine and native mapacalcine on cortical neurons during OGD. A: Results were expressed as the mean value of cells per mm2 ± SEM. Incubations were performed in the absence (Control) or in the presence of 1µM of 9HIS-mapacalcine (9-His mapa), or 1 µm of native mapacalcine (Nat mapa), ***p<0.005 (Student t-test). B: Typical pictures of one counted field in control, 9HIS-mapacalcine and native mapacalcine conditions. C: Comparison of effects of 1 µM of 9HIS-mapacalcine or native mapacalcine on electrophysiological recordings in cortical neurons. The holding potential was −80 mV. Calcium currents were recorded from −70 to +50 mV in control condition (●), in the presence of 9HIS-mapacalcine (formula image) or native mapacalcine (formula image). In each condition, current densities (pA/pF) are shown as a function of membrane potential (mV). Bars represent the SEM values, n=10 for each condition, p<0.05. D: Basal calcium levels. The fluorescence intensity of a calcium indicator Fluo-2/AM was measured in the absence (Control) or in the presence of 1 µM of 9HIS-mapacalcine (9-His mapa) or native mapacalcine (Nat mapa). Results are means ± SEM of 6 independent dishes, ***p< 0.005 (Student t-test).

Similar articles

References

    1. Kawai A., Araki N., Sugiura H., Ueda T., Yonemoto T., Takahashi M., Morioka H., Hiraga H., Hiruma T., Kunisada T., Matsumine A., Tanase T., Hasegawa T., Takahashi S. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol. 2015;16:406–416. - PubMed
    1. Cortes J., O'Shaughnessy J., Loesch D., Blum J.L., Vahdat L.T., Petrakova K., Chollet P., Manikas A., Dieras V., Delozier T., Vladimirov V., Cardoso F., Koh H., Bougnoux P., Dutcus C.E., Seegobin S., Mir D., Meneses N., Wanders J., Twelves C. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914–923. - PubMed
    1. Perdicaris S., Vlachogianni T., Valavanidis A. Bioactive natural substances from marine sponges: new developments and prospects for future pharmaceuticals. Nat. Prod. Chem. Res. 2013;1:114.
    1. Mehbub M.F., Lei J., Franco C., Zhang W. Marine sponge derived natural products between 2001 and 2010: trends and opportunities for discovery of bioactives. Mar. Drugs. 2014;12:4539–4577. - PMC - PubMed
    1. Rui T., Zhang J., Xu X., Yao Y., Kao R., Martin C.M. Reduction in IL-33 expression exaggerates ischaemia/reperfusion-induced myocardial injury in mice with diabetes mellitus. Cardiovasc. Res. 2012;94:370–378. - PubMed

LinkOut - more resources